PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Gyros AB for its Commitment to Improving the Immunoassay Workflow - By adding Gyrolab xPlore™ to its product line, the company has managed to increase its appeal to a wider range of customers - /
Frost & Sullivan Lauds Gyros AB for its Commitment to Improving the Immunoassay Workflow


NewswireToday - /newswire/ - Mountain View, CA, United States, 2015/06/08 - By adding Gyrolab xPlore™ to its product line, the company has managed to increase its appeal to a wider range of customers - /

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Based on its recent analysis of the immunoassay market, Frost & Sullivan recognizes Gyros AB with the 2015 North America Frost & Sullivan Award for New Product Innovation. The newly launched Gyrolab xPlore™ brings automated nanoliter-scale immunoassay technology to low-to-mid throughput applications and laboratories. This cost-effective, follow-on system to Gyros’s flagship Gyrolab™ xP workstation utilizes the same highly advantageous technology of its high-throughput counterpart in a single-CD, smaller footprint instrument.

The microstructured CDs, which Gyrolab xPlore™ uses to conduct immunoassays for protein detection, have several advantages over traditional microplates employed in enzyme-linked immunoassays (ELISAs) and other immunoassay types. The most obvious benefit of its proprietary CD is reagent miniaturization, which brings huge reagent cost savings and automation for increased workflow efficiency and high data quality.

Designed to be 21 CFR part 11-compliant, Gyrolab systems automate sample addition, washing, and laser-induced fluorescence detection steps, providing up to 112 data points from a single CD in one hour. In contrast, performing this same process with an ELISA requires considerable hands-on time, with multiple coating, blocking, washing and incubation steps over a full day. As an open platform, Gyrolab systems allow labs to use reagents of their choice to develop assays or kits supplied by Gyros and EMD Millipore. Researchers only need to place samples and reagents into a microtiter plate, put it into the instrument, and start the run.

Gyrolab xPlore™ is the second instrument in the innovative Gyrolab line of immunoassay systems. Gyros’s flagship product, the Gyrolab™ xP workstation, has revolutionized high-throughput immunoassay workflows for many biopharmaceutical laboratories. This immunoassay platform can analyze up to five Gyrolab CDs (560 data points) concurrently, providing true walk-away automation and maximizing lab productivity. Gyros has placed nearly 200 Gyrolab™ xP workstations globally, with more than one-third of its customers installing multiple instruments. The system is placed in seven of the top 10 pharmaceutical companies, including Pfizer, GlaxoSmithKline, Merck, and many other high-profile companies in its impressive list of customers.

Adding to its value, Gyros technology can provide an entire PK profile from a single mouse, termed “One Mouse, One PK” by Gyros. This decreases the number of mice required for such a profile by 60 to 80 percent, increases the quality of the profile by reducing the variability of PK endpoints, and lowers costs related to animal usage. Beyond the quality and cost advantages, the ethical impact of curtailing animal testing is a major benefit, supporting the global 3R initiative for replacement, reduction and refinement in research using animals.

“Thus far, Gyrolab™ xP has been widely used along the biotherapeutic product development workflow for applications such as pharmacokinetics (PK)/toxicokinetics (TK), biomarker monitoring, immunogenicity, product titer, and impurity testing,” noted Frost & Sullivan Senior Industry Analyst Christi Bird. “However, Gyros expects Gyrolab xPlore™ to expand the use of the technology into research and discovery phases, as well as widen the accessibility and applicability of the platform.”

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

“Gyros AB has done a remarkably good job of understanding customer needs in the immunoassay market and developing innovative new products to address those needs. Its Gyrolab™ xPlore™ and xP workstations are uniquely positioned for sustained success because they address the core issues that customers care about quality, functionality and reliability,” said Frost & Sullivan Global President and Managing Partner Krishna Srinivasan.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Gyros AB
Gyros manufactures laboratory instruments, consumables, kits and software to maximize laboratory productivity by miniaturizing and automating immunoassays at nanoliter-scale. Gyrolab™ systems use proven microfluidic CD technology to analyze large numbers of samples in parallel, ensuring uniform processing and yielding up to 112 data points in less than one hour. Gyros ( will put a new spin on what’s possible in your laboratory.

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Frost & Sullivan Lauds Gyros AB for its Commitment to Improving the Immunoassay Workflow

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Mireya Espinoza - 
210-247-3870 mireya.espinoza[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (